Andrew Schwendenman
Comptroller/Controller/Auditor bij REPLIMUNE GROUP, INC.
Vermogen: 235 164 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Andrew Schwendenman
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 24 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Andrew Schwendenman via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member Corporate Officer/Principal Director/Board Member Director/Board Member | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Founder Chief Executive Officer Corporate Officer/Principal Director/Board Member General Counsel Corporate Officer/Principal | |
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The company is based in Abingdon, UK and was founded in 2015. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| JUNO THERAPEUTICS INC | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Chairman | |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MEDIAN TECHNOLOGIES | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Imperial College London | College/University | Doctorate Degree Graduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder | |
| UNIQURE N.V. | Biotechnology | Chairman Director/Board Member | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
| LAVA THERAPEUTICS N.V. | Biotechnology | Chairman Director/Board Member | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Consultant / Advisor | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Investor Relations Contact Comptroller/Controller/Auditor | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Biotechnology | General Counsel Director/Board Member | |
| DYAX CORP. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | General Counsel Director/Board Member | |
| Bayer Pharmaceuticals Corp. | Corporate Officer/Principal President | ||
| Tufts University School of Medicine | College/University | Graduate Degree Doctorate Degree | |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
The Cancer Prevention & Research Institute of Texas
 The Cancer Prevention & Research Institute of Texas BiotechnologyHealth Technology Cancer Prevention & Research Institute of Texas provides cancer research and prevention programs and services. It is the state agency mandated to create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer. The company was founded in 2007 and is headquartered in Austin, TX. | Biotechnology | Corporate Officer/Principal | |
| Fitchburg State College | College/University | Undergraduate Degree | |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Lesley University | College/University | Graduate Degree | |
| European Organisation for Research & Treatment of Cancer | Corporate Officer/Principal | ||
| CURIS, INC. | Biotechnology | Corporate Officer/Principal | |
Mariana Oncology, Inc.
 Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Biotechnology | Director/Board Member | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member | |
| The Indiana University School of Medicine | College/University | Corporate Officer/Principal | |
| CARGO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Les Laboratoires Servier SAS
 Les Laboratoires Servier SAS Pharmaceuticals: MajorHealth Technology Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 32 |
| Verenigd Koninkrijk | 6 |
| Duitsland | 5 |
| Frankrijk | 4 |
| Nederland | 4 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 6 |
| Commercial Services | 5 |
| Finance | 5 |
| Health Services | 3 |
Operationeel
| Director/Board Member | 160 |
| Corporate Officer/Principal | 74 |
| Independent Dir/Board Member | 51 |
| Chairman | 23 |
| Undergraduate Degree | 20 |
Sterkste connecties
| Insiders | |
|---|---|
| Kapil Dhingra | 39 |
| Otello Stampacchia | 37 |
| Hugo Slootweg | 34 |
| Dieter Weinand | 32 |
| Jason Rhodes | 24 |
| Hyam Levitsky | 18 |
| Joseph Slattery | 18 |
| Jean Franchi | 17 |
| Paolo Pucci | 15 |
| Pamela Esposito | 13 |
| Colin Love | 11 |
| Tanya Lewis | 11 |
| Philip Astley-Sparke | 11 |
| Emily Hill | 9 |
| Christy Oliger | 8 |
- Beurs
- Insiders
- Andrew Schwendenman
- Bedrijfsconnecties
